Merrimack Pharma’s stock plunges (again) on its latest cancer drug trial flop
Merrimack Pharmaceuticals $MACK has another loser on its hands.
The drug MM-121 (seribantumab) added to docetaxel did not do any better than docetaxel alone in improving the progression-free survival of patients suffering from non-small cell lung cancer.
Merrimack’s stock, already blighted by trial failure, quickly plunged anew, dropping more than 30% on the latest setback. The stock was trading at around $3.50 mid-morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.